PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration

PEGylated arginine deiminase (ADI-PEG 20) is being investigated in clinical studies in arginine auxotrophic cancers and is well-tolerated. The anti-tumor properties of ADI-PEG 20 have been extensively investigated - ADI-PEG 20 inhibits the growth of auxotrophic cancers in vitro and in vivo - however...

Descripción completa

Detalles Bibliográficos
Autores principales: Brin, Elena, Wu, Katherine, Lu, Hsin-Tze, He, Yudou, Dai, Zhaoming, He, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601705/
https://www.ncbi.nlm.nih.gov/pubmed/28938609
http://dx.doi.org/10.18632/oncotarget.19564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601705/
https://www.ncbi.nlm.nih.gov/pubmed/28938609
http://dx.doi.org/10.18632/oncotarget.19564

Ejemplares similares